This FOA targets investigators who have at least one single-PI R01-equivalent award (defined here as R01, R37, DP2 or SC1) that expires in the same or the next fiscal year (FY) as the planned submission (i.e., for submission in FY 2019, a project end date of October 1, 2018-September 30, 2020) which received funding in the prior FY (i.e., for submission of an application in FY 2019, an R01, R37 or SC1 grant must have received funding in FY 2018; a DP2 needs to have been initially awarded in 2014 or 2015). Other investigators are ineligible. At the time of the application the PI may have additional NIGMS and/or NIH awards, but may not have another award that requires 50 percent or more research effort (e.g., a DP1 Pioneer Award).
See an overview of determining individual eligibility [PDF, 777KB] using
You may reapply only if you still meet the criteria in the preceding FANote, also, that if you are eligible to apply next year, that application will be considered a new application, not a resubmission.
An eligible award might be in a no-cost extension. An example in 2019 would be a PI of an R01 whose project end date was March 31, 2019. This grant would have received funding in FY 2018, and would make the PI eligible in FY 2019 to apply to the May 17, 2019, receipt date. If requested, this grant could be in its first no-cost extension on this submission date. The PI would also be eligible if this grant had expended all of its funds and terminated. Note that based on this grant, the PI might not be eligible to apply for the MIRA in FY 2020 as the R01 was not funded in 2019.
No, an investigator with only one eligible R01 equivalent in a given fiscal year is eligible to apply for the MIRA.
U01s involve substantial NIH staff involvement. It is unclear how that involvement would be incorporated into MIRA.
DP1 awards that would overlap in time with the MIRA render the investigator ineligible because the investigator's total research effort would exceed 100 percent.
No. Eligibility is restricted to PDs/PIs with at least one NIGMS single-PD/PI R01 equivalent award.
Yes, but only when the single-PI R01 is eligible. Also, see
VII. Award Process Information. In addition, you should discuss the ramifications of the MIRA with your program officer and your collaborators on the multi-PI R01(s) before deciding whether a MIRA makes sense for your research program.
No. You are only eligible to apply when the single-PI R01 is up for renewal. If you have more than one single-PI NIGMS R01, you may apply when any of them are due for renewal.
If the subproject is your only GM award the answer is NO. If you are also a PI on an eligible R01-equivalent award, the answer is Yes, but see
VII. Award Process Information. In addition, you should discuss the ramifications of the MIRA with your program officer and your collaborators on the P01 before deciding whether a MIRA makes sense for your research program.
This FOA targets established investigators with an R01 equivalent award from NIGMS that needs to be renewed to maintain funding. The application could come from an investigator who would be submitting his or her first renewal or who is seeking future funding on the completion of a DP2 or SC1 award; alternatively, it could be submitted by an established PI with an extensive grant history. NIGMS has issued a separate FOA for early stage investigators.
No. This FOA is intended to provide support for the NIGMS mission-related research program of a single independent investigator who has received an R01-equivalent award from NIGMS.
Women and members of underrepresented groups who meet the other eligibility requirements are strongly encouraged to apply.
No, NIH intramural research program scientists are not eligible to apply. A MIRA application can include a collaboration with an intramural scientist, but no funds can be provided to the intramural laboratory via MIRA. A MIRA will not be converted to a cooperative agreement. Therefore, if the intramural researcher would have primary responsibility for a significant component of a MIRA program, a MIRA may not be a suitable means of support.
Yes. Individuals may have support from other NIH components or from other sources. However, they must be able to commit 51 percent of their research effort to the MIRA. Research supported by non-NIGMS sources may not be included in the MIRA application, and NIGMS funds will not be awarded to support the non-NIGMS research. Please note that, consistent with NIGMS' policy on
Support of Research in Well-Funded Laboratories, if your laboratory receives a large amount of research support from non-NIGMS sources such that your total funding is in excess of $750,000 direct costs, your MIRA budget may be reduced.
No. for example, if a PI submits an application for an NIGMS R01 for February 5/March 5, 2019 receipt dates, he or she would not be able to submit a MIRA application on May 17, 2019. If the PI submits a MIRA application on May 17, 2019, then he or she would not be able to submit a continuation of his or her current R01 until after the summary statement for the MIRA is available. The application and eligibility dates in 2019 require a PI to choose between submitting an R01 continuation or applying for a MIRA. Similar restrictions apply to future years.
Yes. HHMI investigators are eligible to apply for MIRA. The relationship between the work supported by HHMI and the work to be supported by NIGMS must be carefully explained but need not be separated into different projects and different specific aims. However, study sections, the National Advisory General Medical Sciences Council and NIGMS staff will take total support, including PI salary support by HHMI, into account when considering the appropriate budget level of a MIRA. Investigators with other types of
substantial, unrestricted laboratory support will be similarly considered on a case-by-case basis.
MIRA funding levels will take into account the policy on
NIGMS Funding for Investigators with Substantial Unrestricted Research Support. It is therefore expected that the budget for a MIRA for an investigator with substantial unrestricted research support will be close to that of an average-size NIGMS R01 award.
No. An investigator can only have one MIRA, which should be submitted by the institution where he or she primarily conducts his or her research program. Under rare circumstances, a subcontract might be permitted to support a part of the research program that is based at a different institution.
The determination of potential eligibility was designed to be unambiguous. By using the
NIH RePORTER website and
following this procedure [PDF, 777KB], the eligibility conferred by an R01-equivalent grant can be confirmed. However, the timing of other grant submissions to NIGMS could affect the eligibility, or receipt of new grants requiring 50 or more percent research effort would result in a loss of eligibility.
Yes. Due to a wide variety of grant starting and ending dates, windows of eligibility will open and close. An applicant is responsible for checking his/her eligibility in each round that an application is submitted.
NIGMS anticipates that the success rate will be approximately the same as that of established investigators' success rates on renewing R01 grants.
For well-funded investigators (generally with more than $400,000 direct costs from NIGMS), an award will likely be somewhat lower than the current/recent total budget in recognition of the stability, flexibility, decrease in administrative burden, and increased length of award that the MIRA provides. Investigators should keep in mind that NIGMS is unlikely in the future to award more than 2 R01s to a PI, so the MIRA is likely to be a better deal for well-funded investigators.
In general, if an investigator's current total research support from NIGMS is between $250,000 and $400,000 in direct costs, his or her award may be about the same, reduced, or slightly increased
If an investigator's current NIGMS research funding is more modest (less than $250,000), he or she might expect an amount similar to or even higher than this level.
Because every situation is different, our budget determinations are done with a great deal of consideration and on a case-by-case basis.
Yes. You may request money for equipment in any year as long as there is appropriate justification. Note that this is not intended as a mechanism to acquire "big-ticket" items that may be covered under instrument-specific funding opportunities.
Applications may request up to $750,000 in direct costs per year for a period of 5 years. However, investigators are expected to request what is actually well-justified for their research program. In general, the request should be commensurate with the investigator's current total NIGMS research funding. Cost efficiency is one of the goals of the MIRA program and will be one of the considerations in review and funding decisions.
April 1-June 1, 2019, is the anticipated start dates for MIRA applications submitted for the May 17, 2018, deadline. Applications submitted for the January 17, 2019, deadline are intended to be issued with start dates between January 1 and March 1 of 2020.
No. Annual increases in any direct cost category are not allowed. If increases are included in the submitted budget, the increases are removed from requested funds and result in decreases in the total budgets of the years where they were included.
MIRA provides support for an investigator's overall program of research. This approach makes MIRA fundamentally different from other funding opportunities offered by NIGMS, which provide support on a project-by-project basis. For the purposes of MIRA FOAs, a research program is defined as the collection of scientific projects in an investigator's lab that are related to the mission of NIGMS. The anticipated advantages of this approach include increased stability of funding; enhanced ability to take on ambitious scientific projects and approach problems creatively; increased flexibility to follow important new research directions as opportunities arise; more widely distributed funding among investigators; increased efficiency and efficacy of NIGMS funding; increased productivity and improved chances for important breakthroughs; reduced time spent writing, reviewing and managing multiple research grants; and more time for the conduct of research and mentoring junior scientists in a more stable environment.
The three key differences are:
1. The scope of the research supported by the MIRA, which encompasses the broad program of NIGMS-mission relevant research in the investigator's laboratory, in contrast to a narrowly focused project(s).
2. The flexibility that program-level support will provide to the investigator, allowing her or him to pursue new research directions as opportunities arise. This flexibility is reflected in the form of the MIRA application, which shifts emphasis away from details of proposed experiments and toward the importance of the overall research questions; specific aims are eliminated, and the review process and review criteria emphasize the potential impact of the work over details of the approach.
3. The possibility of an approach to renewals that will avoid abrupt termination of laboratory support if the renewal is unsuccessful.
MIRA provides support for a major research effort in the investigator's laboratory, leading to a requirement that he or she must devote at least 51 percent of their research effort to the MIRA. Research effort is calculated differently than professional effort in that research effort does not include effort expended toward teaching, administration and/or clinical duties and needs to be converted to calendar months.
For example, if an investigator spends 50 percent of his or her time in the clinic and 50 percent of his or her time on research, he or she must devote a minimum of 25.5 percent effort to MIRA (50 percent research effort x 51 percent MIRA effort requirement = 25.5 percent must be devoted to the MIRA), regardless of the amount of salary support requested. This would be equal to 3.06 calendar months of effort (25.5 percent x 12 calendar months = 3.06 months). In another example, if an investigator spends 25 percent of his/her time on research, he/she must devote at least 12.75 percent effort to MIRA (25 percent research effort x 51 percent MIRA effort requirement = 12.75 percent effort to the MIRA). This is equal to 1.53 calendar months (12.75 percent X 12 calendar months = 1.53 calendar months).
PIs must devote at least 51 percent of their research effort, but a higher level of PI research effort may be requested, if well justified. The total research effort should be calculated based on an investigator's expected level of research effort should the MIRA application be funded. Some institutions may require support on research grant funds to offset a shift in effort from teaching to research. Others may offer teaching or clinical load reductions as an incentive for research. If other duties to the institution will be correspondingly reduced if the MIRA and other pending applications are funded, that change in effort for research must be reflected in the calculation.
Investigators cannot simultaneously hold another award that requires 50 percent research effort (such as an R35 from another institute of the NIH or a DP1 Pioneer Award). NIGMS will not make a MIRA while such awards are active or applications for any such awards are pending. The pending applications must be withdrawn before the MIRA will be issued.
Salary may be requested based on the institutional base salary level for up to an amount commensurate with the number of calendar months of effort committed to the MIRA. A lower level of salary support may be requested; NIGMS does not consider there to be an obligatory relationship between percent of annual effort and percent of annual salary recovered from the grant. In FY 2017, the legislatively authorized maximum institutional base salary that can be requested or charged to an NIH research grant for 12 calendar months' effort is $189,600, excluding fringe benefits. Thus, if the PI's salary is at or higher than the legislative authorized maximum, the 51 percent MIRA requirement of a total 50 percent research effort, corresponds to a maximum salary of $48,348, excluding fringe benefits (50 percent research effort x 51 percent MIRA effort requirement = 25.5 percent on the MIRA; 25.5 percent x $189,600 = $48,348). Assuming for example a 33 percent fringe benefit rate, this would correspond to a maximum of $64,303 annual direct costs.
Any research area within the mission of NIGMS is eligible for support on a MIRA.
Research areas supported by NIGMS are outlined on the NIGMS website. However, some types of research might be more suitably supported using a traditional R01 or other grant mechanism with more specific detail provided (e.g., clinical trials or technology development). See the NIH definition of a clinical trial at
NOT-OD-15-015 . NIGMS offers other mechanisms to support clinical trials.
NIGMS funds research on the structural biology of virus and host cell factors that are essential in the life cycle of HIV and related viruses. This work is within the mission of NIGMS but is supported with dedicated funds appropriated through the Office of AIDS Research. For this reason, the MIRA grant mechanism with its implied freedom to explore other areas of research within the NIGMS mission may not be the most appropriate way to support HIV/AIDS research. Contact NIGMS staff before applying.
Yes. Technology development can be an essential part of any research program and hypothesis-driven science is only one way of approaching a research problem. As noted above, however, a program aimed almost exclusively on technology development may be more appropriately supported by other mechanisms.
Yes. Clinical and translational research within the NIGMS mission may be supported through a MIRA.
NIH-defined clinical trials cannot be part of any MIRA application or award and must be submitted to
clinical trial-specific funding opportunity announcements . Pre-application discussion of clinical/translational research projects with a NIGMS program director is encouraged. Such research can also be added after award of the MIRA, as a change in scope, providing NIH approval is obtained prior to initiating the studies.
Yes. NIGMS strongly endorses collaborative research. However, the MIRA concept is based on the idea that NIGMS will provide support to an individual investigator's research program. Collaborators will work together because of their mutual interest in a problem. In cases where a collaborator's efforts are well-justified, essential to the research program of the MIRA and cannot be supported by the collaborator, a consortium agreement can be included.
A MIRA investigator can collaborate with an intramural scientist, but no funds can be provided to the intramural laboratory from the MIRA. If involvement with an intramural lab is a substantial part of the investigator's research program, a MIRA may not be a suitable means of support.
Yes. NIGMS supports international collaborative research efforts, and investigators are encouraged to pursue scientifically productive collaborations. In cases where a foreign collaborator's efforts are well-justified, represent a unique scientific opportunity, are essential to the research program of the MIRA and cannot be supported by the foreign collaborator, a consortium agreement with a foreign institution can be included.
As indicated in the
NIH glossary, co-Investigators are defined as collaborators and are considered equivalent to senior/key personnel. The Co-Investigator designation does not affect the PI's roles and responsibilities as specified in the NIH Grants Policy Statement, does not imply that there are multiple PIs, and does not confer any advantages or responsibilities on the individual in question beyond those of a collaborator or senior key person. Applicants should therefore consider whether designation as collaborator or key personnel might be sufficient. Applicants should also keep in mind that the MIRA concept is based on the idea that NIGMS will provide support to individual investigators' research programs. Collaborators will work together because of their mutual interest in a problem. In cases where a collaborator's efforts are well-justified, essential to the research program of the MIRA and cannot be supported by the collaborator, a consortium agreement or request for salary support can be included. Please note, however, that as stated in the PAR, these arrangements are expected to be rare. If a consortium/contractual arrangement or salary for a collaborator must be included, the application must also include a letter from the collaborator indicating why they cannot participate in collaborative research with the PD/PI without support from the MIRA. If the justification provided is deemed insufficient by review or by NIGMS leadership, the requested funds may be removed prior to award.
This needs to be considered on a case-by-case basis and requires the application of reasonable judgment by both investigators and NIGMS staff. The extension of studies on a problem from one organism to another would be very reasonable. Insights gained from studying one biological problem that extend the project into another within the mission of NIGMS would also be reasonable. When in doubt, you should discuss changes with the appropriate NIGMS program director.
Potential indicators of changes in scope include the addition, or a change in the approved use, of human subjects, vertebrate animals, select agents or human embryonic stem cells. These changes require appropriate documentation and prior approval by NIGMS before the work is initiated. Work that migrates fully into the mission of another NIH institute or center would be considered out of scope and it would be appropriate for this work to transition out of MIRA to grants supported by the relevant NIH institute or center.
On submission of a MIRA application, the PI cannot submit another research grant to NIGMS until the MIRA application has been reviewed and a summary statement issued. Upon receiving a MIRA, NIGMS will not fund an application for a research award where the MIRA PI is the PI or a multi-PI. The MIRA PI can participate in other NIGMS research applications as a collaborator (i.e., Other Significant Contributor) but cannot receive any funds from the grant.
A MIRA PI can participate in an NIGMS large-scale research grant as a Core Leader if the purpose of the Core is solely to provide a service. The MIRA PI can participate in Center and other large-scale research projects as an Other Significant Contributor (i.e., collaborator), but cannot receive any funds from the grant.
These applications are explicitly allowed:
Grants supporting research resources;
Cooperative agreements if permitted by the specific FOA;
Grants supporting training, workforce development or diversity building;
Grants for clinical trials;
INBRE (P20), COBRE (P20/P30) or IDeA-CTRs (U54);
Grants supported through NIGMS HIV/AIDS-related FOAs.
Research Supplements to Promote Diversity in Health-Related Research, and certain types of administrative supplements, including equipment supplements that may be offered by NIGMS through FOAs in the NIH Guide.
MIRA PIs are not prevented from submitting applications to other NIH Institutes.
Ask yourself how much time and effort it takes you to maintain the current NIGMS funding of your laboratory through multiple, separate grant applications. Decide whether a single NIGMS project, with a budgetary constraint on well-funded labs, is worth the advantages provided by the MIRA program. The advantages include 5 years of funding, more scientific flexibility, greater stability and reduced administrative burden. NIGMS expects that well-funded research groups supported by the established investigator MIRA FOA will be somewhat reduced in size relative to their recent scales.
MIRA-supported investigators will have the flexibility to pursue the science they want to do as it evolves, rather than being held to specific aims that they proposed before they received a grant. In this way, they will have greater flexibility to try ideas that might be considered high-risk. MIRA is expected to result in more stable funding of investigators, better continuity of effort and better ability to keep well-trained personnel in the laboratory. MIRA is also expected to broaden the distribution of funding among laboratories, enabling more of the nation's highly talented and promising investigators to participate.
An investigator may be the PI on only one application for a MIRA in any one review cycle. There is no limit on the number of applications that can be submitted by an institution, provided they are for support of the research programs of different independent eligible investigators.
You may discuss your ideas with the program officer who administers your current NIGMS applications and awards.
Specific aims are not allowed because a goal of MIRA is to move the scientific enterprise away from a focus on narrowly defined research projects with detailed specific aims and to refocus attention on the larger picture and potential overall impact of the research. If your institution's system for submitting a grant application gives you a warning and will not allow you to skip the specific aims page, enter the following text in the appropriate place: "Per the FOA instructions, no specific aims are to be submitted."
Follow the instructions in the SF424 R&R application guide as modified by the instructions in the FOA. In brief, this means that the scientific content of the application will rely mainly on the abstract, public health relevance statement, facilities and other resources page, biosketch and the six-page research strategy, plus details on the involvement of human subjects and vertebrate animals as necessary. Applications must also provide data/resource sharing and key resource validation plans. Avoid duplicating material covered in other sections. Do not include lists of publications, except as part of the biosketch, or references except as necessary in the Bibliography & References Cited section of the Other Project Information Form. Provide information on current and pending research support at the time of application in the format typically used for Just-in-Time information. Be sure to distinguish the direct costs per year that support research in the investigator's laboratory from support that goes to other investigators. See the
MIRA webpage for an example [PDF, 62.5KB].
Because the goal of MIRA is to focus the investigator's and reviewers' attention on the higher level questions about significance and impact of the research program, details in the research plan can be reduced. Furthermore, changes in the biosketch mean that much of the needed information about the recent past research contributions of the investigator can be presented there, rather than in the research plan.
Yes. All MIRA applications must include a plan describing how key biological and/or chemical resources are identified and validated.
There is no change in the format/requirements for the Vertebrate Animals Section (VAS) of the MIRA application. MIRA applicants should follow current
supplemental instructions on preparing the Vertebrate Animals section of the research plan. If you plan to use live vertebrate animals (including production of custom antibodies and animals obtained for their tissues), but do not yet have detailed plans, you must still include a Vertebrate Animals Section. You will need to answer "yes" to the question "Vertebrate animals, yes or no" in Item 2 of the Other Project Information component in your grant application package. Your application also covers all performance sites, including sub-award partners, collaborators, contractors and others involved in animal research. Even if the only animal work that will be done from your R35 application will be performed somewhere other than your institution (e.g., you plan to have an antibody made by an outside contractor) you will need to mark "yes." You will need to follow the instructions for Vertebrate Animals in the
SF424 Form Instructions and include a Vertebrate Animal Section (VAS, see Vertebrate Animal Worksheet).
NIH expects that sex as a biological variable will be factored into research designs, analyses and reporting in vertebrate animal and human studies. Strong justification from the scientific literature, preliminary data or other relevant considerations must be provided in the Research Strategy for applications proposing to study only one sex. If you have designed your studies and they will be discussed in your R35 application, you should provide this information in your VAS for points 1 to 3 (Description of Procedures, Justifications, and Minimization of Pain and Distress) so the study section can rate your VAS as acceptable or unacceptable.
If you plan to use animal studies in your MIRA application but have not defined your plans about the species, sex, protocols and procedures to minimize pain and distress, or other information required for submission for your institutional animal care and use committee (IACUC) approval and a completed VAS in your application, please indicate that animals will be used in your application on the appropriate pages of your application and include a VAS in your application with as much of the information that you can provide. But for those topics that you do not have definite information, indicate that animal studies will have a delayed onset.
At the appropriate time after review, you will be asked for your IACUC approval of your research protocols. If your plans remain uncertain, a restricted notice of grant award will be issued that bars the use of funds for vertebrate animal research until prior NIH approval is obtained.
Yes. Clinical and translational research within the NIGMS mission may be supported through a MIRA.
NIH-defined clinical trials cannot be part of any MIRA application and must be submitted to
clinical trial-specific funding opportunity announcements. Pre-application discussion of clinical/translational research projects with an NIGMS program director is encouraged.
There is no change in the format/requirements for the Protection of Human Subjects section in the MIRA application. MIRA applicants should use the
PHS Human Subjects and Clinical Trials Information form. Please note that study records should be entered for delayed start human subjects studies, i.e. a study that can be described at the time of application but will not begin at the time of award. The
delayed onset human subjects study section only applies to studies for which definite plans for human subjects involvement cannot be described at the time of application.
Yes, both delayed start and
delayed-onset human subjects research are permitted in MIRA awards. MIRA awardees should submit a prior approval request to their program director to add human subjects research to their MIRA. Prior approval requests should contain IRB approval of the human subjects study as well as a complete
PHS Human Subjects and Clinical Trials Information form.
MIRA awardees can submit a prior approval request to their program director to add human subjects research to their MIRA or to initiate
"delayed onset" studies. Prior approval requests should contain IRB approval of the human subjects study as well as a complete
PHS Human Subjects and Clinical Trials Information form.
Appendix materials are limited to the same items as for other NIH grant mechanisms. Do not use the appendix to circumvent the page limits. See
Letters of support should be included from all collaborators who will receive financial support from the MIRA and are listed as key personnel. The application must also include a letter from the institution's authorized organizational official indicating that the institution is aware of and accepts the condition that other NIGMS research awards must be relinquished as a condition of receiving a MIRA and providing a statement that if chosen to receive an award, the PI will commit a minimum of 51 percent of his or her research effort to MIRA activities.
The institutional letter of support must be included as an attachment to the PHS 398 Research Plan Form (Item 13 Letters of Support). See
SF424 (version D) instruction guide section G.400 pp G-151.
Applications that miss the due date and time are subjected to the
NIH Policy on Late Application Submission.
Yes. You may request money for equipment in the first year and in any subsequent years with appropriate justification. This is not intended as a mechanism to support the purchase of "big-ticket" items that may be covered under instrument-specific funding opportunities.
Yes, but such requests must be extremely well-justified. NIGMS continues to encourage collaborative and interdisciplinary research when it is appropriate, and individual MIRA grantees are free to collaborate with one another or with other investigators using funds from their individual grants to support their parts of the team's research. A letter from the collaborating PI should be included, making his/her contributions to the program clear and detailing the reasons he or she cannot participate in collaborative research with the PI without support from MIRA.
Senior/key personnel who are independent investigators can contribute effort toward MIRA. They may receive support from the award, but only if they do not also receive support from their own MIRA.
For this PAR, key personnel should be limited to the PD/PI and subcontracted independent investigators. You should not include individuals who meet the definition of
Other Significant Contributors.
For this PAR, in addition to the PI, biosketches of collaborators supported by the MIRA are the only additional ones required. Because the focus of the MIRA application is the research program of the PI, the inclusion other biosketches may distract reviewers from the contributions of the PI.
The MIRA program wants to provide recognition during the review to PIs who have made significant contributions to the research community. These contributions are not limited to, but are exemplified by, the following examples:
Providing a research resource that is widely used, e.g., maintaining a model organism database.
Running an effective program that gives high school or undergraduate students from diverse backgrounds experience and mentoring in biomedical research.
Significant service to scientific professional societies, peer review panels or journal editorial boards.
For this FOA,
Dr. Vernon Anderson will serve as the initial scientific point of contact. Once applications are received, they will be referred to the most relevant program official based on internal NIGMS referral procedures and guidelines. The program official assigned to your application should be visible to you in the eRA Commons by the time the application is reviewed, and the name and contact information for the program official should appear at the top of the summary statement.
The normal NIH policy on post-submission of grant application materials is applicable. Updates related to administrative changes and publication of articles up to 30 days before the study section meeting may be submitted to the study section SRO. See
Post-Submission Materials Policy FAQ.
Per NIH notice
NOT-OD-12-141 , videos will be accepted by the scientific review officer (SRO) managing the review. Contact the SRO for instructions. The aggregate of your video submission files cannot exceed 2 minutes in length. The videos should be embedded as a single PDF and cannot exceed 25 MB in size and must be received by 30 days prior to the review meeting. See
Interim Guidance for Videos Submitted as NIH Application Materials.
PAR-17-094, reviews will be by special emphasis panels organized by the Center for Scientific Review. The name and contact information for the scientific review official assigned to each application will be posted in the eRA Commons once the assignment has been made.
Applications received for the January receipt dates will be reviewed in June/July for consideration by the National Advisory General Medical Sciences Council in September, with the earliest possible awards beginning in January of the following year. Applications received in May will be reviewed in October/November for consideration by the National Advisory General Medical Sciences Council in January of the following year, with the earliest possible awards beginning in April.
Yes. The Center for Scientific Review will ensure that reviewers have the relevant expertise to review the application, bearing in mind that a MIRA is intended to support a broad program of research and the breadth of research areas that are encompassed by the NIGMS mission. Thus, reviewers will be expected to bring a broad perspective rather than detailed expertise.
Rosters will be available 15 days before the study section meeting.
All applicants will receive a summary statement containing the reviewers' critiques, as well as a resume and summary of the discussion. Since all applications to PAR-17-094 are from previously successful PIs seeking continuation of NIGMS funding, the anticipation is that many, but not all, of these MIRA applications will be discussed. Reviewers will be asked to provide a single overall impact score and will not provide individual criterion scores. This is intended to shift emphasis away from details of the application and the approach, and to emphasize the potential impact of the investigator's research program on the field. Reviewers will be asked for guidance on whether the budget should be increased, decreased or stay essentially the same as the average level of NIGMS support over the previous several years. However, award levels will be based primarily on the parameters described in the Section II, Award and Budget Information.
The review criteria are the same, but the wording has been modified to emphasize the review of the investigator's overall NIGMS-relevant research program rather than a specific, narrowly focused project with highly tailored specific aims. Reviewers should emphasize MIRA-specific aspects of significance, investigator qualifications, innovation, approach and environment.
Yes. Appeals are allowed for PARs.
No, but if you are eligible, you may submit a new application for a receipt date in the next fiscal year.
NIGMS has a long-established policy that requires additional scrutiny of grant applications from investigators whose overall research support including an award for the pending application would exceed $750,000 in direct costs per year. See the
NAGMS Council Guidelines for Funding Decisions. In keeping with this policy additional scrutiny will be given to MIRA applications from well-funded investigators.
The summary statements for MIRA applications will be made available to the National Advisory General Medical Sciences Council in the same way as for other applications.
NIGMS will notify applicants when to submit Just-in-Time information. This information will be requested for all applications under consideration for funding, but the request is not meant to imply anything about the probability of an award. Be sure that the information provides a complete and accurate accounting of the annual direct costs that support research in the investigator's laboratory, as well as any pending applications. See the
MIRA webpage for an example.
NIGMS staff will carefully consider the study section and advisory council recommendations, including the scores and language in the summary statement, Just-in-Time information and recent history of NIGMS, NIH and other grant support, in making recommendations about whether to fund a grant and at what level.
As with all funding decisions, NIGMS also considers the breadth and diversity of the Institute's research portfolio.
Investigators who contact NIGMS staff will be provided feedback in the usual way on the reviews and their prospects for receiving a MIRA. As always, NIGMS staff cannot make any definite statements until the plan to make an award is approved at an appropriate level. The Notice of Award is the only official notice of a government commitment to fund a MIRA.
Once the PI is notified by program staff that NIGMS intends to fund a MIRA and the recommended funding level, the PI should reply by email with his/her intention to accept the MIRA within one week. If the PI declines the planned award, the institution should withdraw the application immediately. If the MIRA is declined, the PI has the option to pursue other mechanisms to obtain NIGMS funding, but NIGMS will not assume any obligations as a result of this decision.
Applicants will not be informed that they will NOT receive an award, because an award may be made at a later date. MIRA applications in response to this PAR will remain under consideration until the end of the fiscal year following the year of submission of the MIRA application.
Each investigator's situation will be carefully considered on a case-by-case basis, but it is expected that bridge funding will be rare. In making a decision, NIGMS will consider, among other factors, the end dates of recent and currently funded projects, recent attempts to renew the relevant R01s, overall support to the laboratory, and the amounts of unobligated balances.
The initial budget determination is of the MIRA funding level, defined as the level of annual funding for the period of the MIRA. The MIRA funding level corresponds to the annual direct costs in the absence of other continued NIGMS funding. The MIRA award level reflects adjustments that are made to the MIRA funding level to account for overlap with the PI's current NIGMS grants along with the addition of the appropriate Facilities and Administrative Costs. The MIRA award level can vary each grant year and reflects the annual total costs in the Notice of Award.
In general, if an investigator's current total research support from NIGMS is between $250,000 and $400,000 in direct costs, his or her award may be about the same, reduced, or slightly increased.
The MIRA funding level will generally be maintained at the recommended annual direct costs level, subject to consideration of what the level of support should be after any modifications of the first year's budget due to equipment requests and/or pro-rating of the overlap in time of the terminated R01-equivalent. The conclusion of on-going multiple PI and program project or center subprojects may also affect the award level in years 2-5. As indicated in the FOA, annual increases (i.e., inflation, increases due to promotions, COLA, etc.) should not have been included in the requested budgets. Furthermore, if one cost category increases while another cost category decreases while maintaining a constant total direct cost level, adjustments will be made to the award calculations to remove the requested cost category increase.
Yes. Automatic carry over authority will apply to MIRA. Standard NIH and NIGMS policies will apply.
If the MIRA application proposed to continue work on an NIGMS grant for which he or she is currently a co-investigator, the applicant's effort will be subsumed into the MIRA. When the MIRA is funded, NIGMS will inform the PI of the other grant that the MIRA PI can no longer receive funding as a co-investigator on the grant and that the PI may rebudget those funds in accordance with all relevant established policies. If after being awarded a MIRA, the MIRA PI wishes to be listed as an unpaid collaborator on another PI's NIGMS grant application, this is permitted, but the MIRA PI cannot request salary or receive funds in any form from another NIGMS award.
With acceptance of the MIRA, the special terms and conditions on the MIRA Notice of Award stipulate the existing NIGMS grants from which the MIRA PI can continue to receive funding. A MIRA PI who is a co-investigator cannot receive funds from NIGMS grants not specified on the MIRA Notice of Award.
Co-investigators other than the MIRA PI may receive support from other awards, including other MIRA grants on which they are not the PI. Independent investigators who receive any support from more than one NIGMS grant are encouraged to consider consolidating their support by applying for a MIRA application when they become eligible under future FOAs.
Co-investigators who are independent investigators can contribute effort toward MIRA. In cases where a collaborator's efforts are well-justified, essential to the research program of the MIRA and cannot be supported by the collaborator, a consortium agreement or request for salary support can be included, so long as the collaborator is not already a MIRA recipient. If a consortium/contractual arrangement or salary for a collaborator must be included, the application must also include a letter from the collaborator indicating why they cannot participate in collaborative research with the PD/PI without support from the MIRA. The PAR indicates that these arrangements are expected to be rare.
These will be included in the MIRA funding level consideration and also in offsets taken to determine the MIRA award level in each year.
NIGMS P01 and center grants where the MIRA PI is a PI or project leader (whether contact PI or not) will continue through the end of the current project period. These funds will be considered in setting the MIRA funding level and an offset will be taken in the first year and each of the remaining years on a prorated basis. Depending on the funding recommendation, once the P01 or center grant award ends, the MIRA award level may or may not increase.
NIGMS multiple-PI R01s where the MIRA PI is one of the PIs (whether contact PI or not) will continue through the end of the current project period. These funds will be considered in setting the MIRA funding level and an offset will be taken in the first year and each of the remaining years on a prorated basis. Depending on the funding recommendation, once the multi-PI R01 award ends, the MIRA award level may or may not increase.
The remaining multiple-PIs can submit a renewal application. The MIRA PI can continue to be listed as an unpaid collaborator in the renewal application, but the MIRA PI cannot request any salary or receive funds in any form from the renewal application. The MIRA PIs support must be provided from the MIRA grant.
Non-affected grants include NIGMS grants that support research resources, cooperative agreements, grants that support training, workforce development or diversity building, clinical trials, SBIR/STTRs, conference grants and the portion of a center grant or a P01 that is strictly a core. Funds currently supporting these activities will not be included in the MIRA funding level.
The MIRA is meant to provide support for the PI's effort on NIGMS-related research. As a result, the effort on those NIGMS grants that are being phased out in order to start the MIRA are subsumed under the effort on the MIRA. For example, assume the following: The MIRA PI currently devotes research effort on several grants:
1.8 calendar months on NIGMS R01 (effort to be subsumed under the MIRA)
2.2 calendar months on NIGMS R01 (effort to be subsumed under the MIRA) 3.0 calendar months on P01 from another institute in NIH
Total of 7.0 calendar months research effort
Since the 1.8 and 2.2 calendar months contributed to the NIGMS R01s will be subsumed into the MIRA, the PIs remaining research effort is the 3.0 calendar months on the P01 from another Institute in NIH. Therefore, the level of effort on the MIRA must be at least 51 percent of these 7 months of research effort (51 percent x 7 = 3.57 calendar months).
Yes. Grants on which a project period is ended early may initiate the first no cost extension, thereby remaining active and retaining the unobligated balance. Funds should continue to be expended on the aims of the active grants that are or will be in no cost extensions.
MIRAs will be eligible for Research Supplements to Promote Diversity in Health-Related Research and may be eligible for certain types of administrative supplements, such as equipment supplements that may be offered by NIGMS through notices in the NIH Guide for Grants and Contracts. Equipment needs that can be anticipated in advance should be included in the MIRA budget request and will be considered in setting the MIRA funding level.
Senior/key personnel other than the PI may receive support from other awards, including other MIRA grants on which they are also not the PI. Independent investigators who receive any support from more than one NIGMS grant are encouraged to consider consolidating their support by applying for a MIRA application when they become eligible under future FOAs.
NIGMS plans for MIRAs to be renewable through a competing application and peer review. An FOA will be issued in time for applications to be received and awards to be made without a gap in funding.
Yes, MIRAs with modest budgets that have been very productive and score very well could receive budget increases. As described above, MIRA budgets will be set based on a number of factors and scoring well on renewal will alone not guarantee a budget increase.
Once a MIRA has been issued, that grant cannot be converted to an R01 award. The terms and conditions of the MIRA will continue through the end of the project period unless the institution chooses to relinquish the grant early. At the end of the project period, the investigator will have the option to apply for continuation of the MIRA or to apply for a new R01 or other forms of support.
Annual reports will be required using the Research Performance Progress Report (RPPR). The FOA includes some additional instructions consistent with the broader goals of the research program supported by MIRA and the absence of detailed specific aims. Additional information is requested that describes any new program directions to the NIGMS research mission, discussion of how the work continues to be of high impact, and the relationship of any new other support to the activities supported by MIRA. These reporting requirements are more specific for MIRA than for an R01 research project grant.
Changes in other support must be reported in the RPPR. The relationship between other support and work supported by MIRA should be explained. NIGMS will assess whether there is sufficient scientific and budgetary overlap to warrant adjustment of the MIRA. The requirement for 51 percent research effort precludes the application for other research grants that require 50 percent research effort.
Formally, the MIRA is awarded to the institution in support of a project, not to an individual person. The institution has the right to request prior approval by NIH for the replacement of the PI. However, given the very intimate association of the ideas, expertise and record of productivity of the specific investigator with the program of research described in the research plan of the MIRA application and the scientific merit of the application as determined during peer review, it is doubtful that NIGMS would approve a permanent change of PI. A temporary change may be allowed with prior approval under circumstances such as sabbatical leave, medical condition, disability or personal or family situations such as child or eldercare needs.
Standard NIH and NIGMS policies will apply.
Senior/key personnel named in the Notice of Award may be replaced or eliminated from the budget with NIH written prior approval. Standard NIH and NIGMS policies apply. SeeNIH Grants Policy Statement in key personnel for full details.
There are no changes to standard NIH policy on prior approval requirements.
Prior approval is needed for the following:
A change in scope, including, but not limited to, a change from the approved use of vertebrate animals or involvement of human subjects, select agents or human embryonic stem cells. See following Q&A for more detail.
Additional no cost-extensions beyond a first no-cost extension or late notification of an initial no-cost extension.
Change in status of the PI or senior/key personnel named in the Notice of Award.
Change in grantee organization or organization status.
Addition of a foreign component if not included in the original application, including a significant new foreign collaboration, requires NIGMS' prior approval; however, MIRA funds may be used to support a subcontract at a foreign institution only if the collaboration is essential to the PI's research program, represents a unique scientific opportunity and cannot be supported by the collaborator.
You will need to notify your NIGMS program officer and grants management specialist of any significant changes to your animal research. Addition of animal studies and/or initiation of "delayed onset" studies requires NIGMS and NIH Office of Laboratory Welfare (NIH OLAW) administrative review prior to the start of these animal studies if you will be using funds from your MIRA. Approval from your IACUC for any new animal studies that will be carried out or for any significant changes to your approved animal studies is also necessary. You will need to provide an updated VAS section and NIH OLAW will need to provide their written approval that you may proceed with your animal studies using your NIGMS MIRA funds including for the purchase of any animals. For details, please see NIH Notice
If you conduct research involving animals on your MIRA without your IACUC approval, NIH may reduce the amount of your award or request return of funds, and you may not use any animal data obtained during this time for any activity related to the grant award.
MIRA awardees can submit a prior approval request in writing to their program director to add human subjects research to their MIRA or to initiate "delayed onset" studies. Prior approval requests should contain a complete Protection of Human Subjects section as described in the current MIRA funding opportunity announcement.
If you currently have grants administered by two or more different NIGMS program officials, the program director for your MIRA will be assigned by considering the scientific areas included in the MIRA application, NIGMS internal referral guidelines and discussion among NIGMS staff.
This page last reviewed on
1/11/2019 1:13 PM
Connect With Us: